tyenne
fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imunosupresivi - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.
zarzio 480 µg/0.5 ml rastvor za injekciju /infuziju u napunjenoj šprici
novartis ba d.o.o. - filgrastim - rastvor za injekciju /infuziju u napunjenoj šprici - 480 µg/0.5 ml - 0,5 ml rastvora za injekciju ili infuziju sadrži 480 mcg rekombinantni filgrastim
zarzio 480 µg/0.5 ml rastvor za injekciju /infuziju u napunjenoj šprici
novartis ba d.o.o. - filgrastim - rastvor za injekciju /infuziju u napunjenoj šprici - 480 µg/0.5 ml - 0,5 ml rastvora za injekciju ili infuziju sadrži 480 mcg (48 mu) rekombinantni filgrastim
zarzio 300 µg/0.5 ml rastvor za injekciju /infuziju u napunjenoj šprici
novartis ba d.o.o. - filgrastim - rastvor za injekciju /infuziju u napunjenoj šprici - 300 µg/0.5 ml - 0,5 ml rastvora za injekciju ili infuziju sadrži: 300 mcg (30 mu) rekombinantni filgrastim
zarzio 300 µg/0.5 ml rastvor za injekciju /infuziju u napunjenoj šprici
novartis ba d.o.o. - filgrastim - rastvor za injekciju /infuziju u napunjenoj šprici - 300 µg/0.5 ml - 0,5 ml rastvora za injekciju ili infuziju sadrži 300 mcg (30 mu) rekombinantni filgrastim
grafalon 20 mg/ml koncentrat za otopinu za infuziju
neovii biotech gmbh, am haag 6+7, gräfelfing, njemačka - imunoglobulin protiv limfocita t, kunićji, za primjenu u ljudi - koncentrat za otopinu za infuziju - 20 mg/ml - urbroj: jedan ml koncentrata sadržava 20 mg kunićjeg imunoglobulina protiv ljudskih t-limfocita
tiotepa fresenius kabi 100 mg prašak za koncentrat za otopinu za infuziju
fresenius kabi d.o.o., radnička cesta 37a, zagreb, hrvatska - tiotepa - prašak za koncentrat za otopinu za infuziju - urbroj: jedna bočica praška sadrži 100 mg tiotepe nakon rekonstitucije s 10 ml vode za injekcije, svaki ml otopine sadrži 10 mg tiotepe (10 mg/ml)
voramol 50 mg filmom obložene tablete
alvogen ipco s.ar.l., 5, rue heienhaff, senningerberg, luksemburg - voriconazolum - filmom obložena tableta - 50 mg - urbroj: svaka tableta sadrži 50 mg vorikonazola
vorikonazol pliva 50 mg filmom obložene tablete
pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb - vorikonazol - filmom obložena tableta - 50 mg - urbroj: jedna tableta sadrži 50 mg vorikonazola
vornal 200 mg filmom obložene tablete
sandoz d.o.o., maksimirska 120, zagreb - voriconazolum - filmom obložena tableta - 200 mg - urbroj: jedna filmom obložena tableta sadrži 200 mg vorikonazola